- $37.63bn
- $40.69bn
- $3.28bn
- 95
- 16
- 100
- 80
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 994 | 1,451 | 2,793 | 2,817 | 3,283 |
Cost of Revenue | |||||
Gross Profit | 753 | 896 | 1,805 | 1,689 | 2,224 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 800 | 1,513 | 2,660 | 2,865 | 2,639 |
Operating Profit | 194 | -62 | 133 | -47.8 | 644 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 126 | -136 | 46.3 | -205 | 381 |
Provision for Income Taxes | |||||
Net Income After Taxes | 119 | -126 | 35.3 | -193 | 357 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 119 | -125 | 35.4 | -193 | 357 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 76.4 | -125 | 31.9 | -193 | 355 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.223 | -0.185 | 0.168 | 0.14 | 0.999 |
Dividends per Share |